What healthcare professionals should consider before entering the psychedelic space

Last reviewed: August 29, 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed physicians, therapists, nurses, psychologists, social workers, naturopaths, pharmacists, and other healthcare professionals who are weighing any form of involvement with psychedelic services — as facilitators, referring clinicians, practice advisors, or business owners.

The short answer

Healthcare professionals entering the psychedelic space face a set of legal questions that their existing professional training did not cover. The risks and considerations vary significantly depending on what level of involvement is contemplated — discussing psilocybin with patients is now explicitly protected for many Oregon clinicians under HB 2387, while obtaining a facilitator license, opening a service center, or investing in a psychedelic business each carry distinct and more complex legal implications. Before taking any of these steps, a clinician should understand how their professional license interacts with the activity they are considering, what federal law means for their specific situation, and what their employer and malpractice carrier will and will not tolerate.

The spectrum of involvement

Healthcare professionals enter the psychedelic space in different ways, each carrying different legal weight.

Discussing psilocybin services with patients is the lowest-stakes entry point. Under HB 2387 (operative January 1, 2026), clinicians regulated by seven identified Oregon boards are explicitly protected from board discipline for discussing psilocybin services as a treatment option with patients. The seven boards are: the Oregon Board of Licensed Professional Counselors and Therapists; the Oregon Board of Naturopathic Medicine; the Oregon Board of Psychology; the Oregon Medical Board; the Oregon State Board of Nursing; the State Board of Licensed Social Workers; and the State Board of Pharmacy. For clinicians regulated by these boards, this is now a settled question in Oregon.

Referring patients to Oregon’s licensed program is also within the protected discussion framework. A clinician can point a patient to the OPS Licensee Directory, review medication considerations in advance, and provide integration-oriented clinical support after a session — all without a facilitator license.

Obtaining a psilocybin facilitator license introduces a separate regulatory relationship with OPS under ORS 475A. HB 2387 created dual licensure provisions allowing clinicians regulated by the seven boards to bring clinical skills into preparation and integration sessions while keeping the administration session facilitation-only. However, the clinician must complete full OPS facilitator training — there is no exemption or shortened path for healthcare license holders in Oregon’s program. Colorado’s program offers a separate Clinical Facilitator track for licensed health professionals with different training requirements.

Opening or investing in a service center, healing center, or psychedelic business raises entity structuring, licensing, zoning, banking, and federal law questions that go significantly beyond what HB 2387 addresses. A clinician who becomes an owner or investor in a licensed psilocybin business has exposure that runs through multiple regulatory frameworks simultaneously.

Federal law does not change because Oregon law changed

Psilocybin remains a Schedule I controlled substance under federal law regardless of Oregon’s or Colorado’s state-licensed programs. For most Oregon clinicians working within the state-licensed program — discussing services with patients, referring to service centers, or facilitating at licensed facilities — the practical federal risk is low. The federal government has not pursued enforcement actions against participants in Oregon’s licensed psilocybin program as of early 2026.

The federal risk picture changes in specific contexts. Federal employees and contractors are governed by federal drug-free workplace rules that Oregon law does not displace — and Oregon provides no employment protection for psilocybin use in any event. Clinicians who receive federal funding — through Medicare, Medicaid, federal grants, or federal contracts — operate in a regulatory environment where the interaction between their federal funding and any psilocybin involvement requires careful attention. Clinicians at federally licensed healthcare facilities face additional constraints. A clinician in any of these categories should get specific legal advice before any involvement beyond patient discussion.

Professional board considerations

Even with HB 2387’s protections in place, a clinician’s professional licensing board retains authority over their conduct in ways that OPS and HB 2387 do not fully address. The seven boards named in HB 2387 are prohibited from disciplining their licensees for lawfully discussing or providing psilocybin services as a licensed facilitator — but that protection applies to lawful conduct under ORS 475A. Conduct that violates OPS rules, conduct that crosses into clinical practice during an administration session, or conduct that implicates the clinician’s professional standards in other ways remains subject to board oversight.

For clinicians regulated by boards not named in HB 2387, the protections do not apply. A dentist, chiropractor, optometrist, or licensed professional engineer who accesses psilocybin services as a client — or seeks a facilitator license — is doing so without the board discipline protections that HB 2387 provides. The analysis for those clinicians runs through article 75 of this library, which covers professional license risk from psychedelic participation generally.

Employment and malpractice insurance

A clinician’s employer may have views on psychedelic involvement that are more restrictive than what Oregon law permits. Hospital systems, group practices, and institutional employers often have conduct policies that restrict employee activity in ways that go beyond the minimum legal requirements. A clinician who intends to obtain a facilitator license, open a psychedelic business, or publicly associate themselves with the psychedelic space should review their employment agreement and their employer’s policies before proceeding.

Malpractice insurance is a related concern. Standard professional liability policies for healthcare providers frequently exclude coverage for work involving Schedule I substances. A clinician whose psilocybin-related work falls outside their existing policy coverage — whether as a dual-licensed facilitator or simply as a clinician providing integration-supportive care to patients — should confirm with their insurer whether that work is covered and, if not, obtain appropriate specialty coverage.

What to sort out before getting involved

Before taking any step into the psychedelic space beyond patient discussion, a healthcare professional should know the answers to five questions. First, does the activity they are contemplating require a separate OPS or DORA license, and what does obtaining that license require? Second, how does their professional board’s rules interact with the activity — including boards not named in HB 2387? Third, does their employer’s conduct policy permit the activity? Fourth, does their malpractice or professional liability carrier cover the activity? Fifth, does any federal funding, federal employment, or federal regulatory obligation create constraints that state law cannot override?

None of these questions are unanswerable. Most have clear answers once the clinician has the right information. The goal is to answer them before a problem arises rather than after.

When public information may be enough

HB 2387’s text is publicly available through the Oregon Legislative Assembly. OPS publishes its dual licensure fact sheet and facilitator licensing information at oregon.gov/psilocybin. DORA publishes Colorado’s Clinical Facilitator track requirements at dpo.colorado.gov/NaturalMedicine. Oregon’s quarterly program data is available at oregon.gov/psilocybin.

When you should speak with a lawyer

Any healthcare professional who is contemplating obtaining a facilitator license, opening or investing in a psychedelic business, or structuring a dual-licensed practice should consult an attorney familiar with both ORS 475A and their relevant professional licensing statutes before proceeding. A clinician who is uncertain whether their federal funding relationships create constraints on psychedelic involvement should get specific legal advice before taking any step beyond patient discussion. A clinician who has already taken steps and is uncertain of the legal implications is better positioned consulting an attorney now than waiting for a complaint to arrive.

You might also want to read

This article is for general informational purposes only and does not constitute legal advice. Laws and regulations governing psilocybin services change frequently. For advice about your specific situation, consult a licensed attorney.